IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
January 15, 2004
April 19, 2019
fa85146f-e37f-41a7-a38d-60e7f38b337d
Related Documents
Premarketing Risk Assessment: Guidance for Industry
Guidance DocumentMarch 29, 2005Center for Drug Evaluation and Research
Q1E Evaluation of Stability Data
Guidance DocumentJune 8, 2004Center for Drug Evaluation and Research
Cancer Drug and Biological Products - Clinical Data in Marketing Applications
Guidance DocumentOctober 11, 2001Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox